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ABSTRACT
Major changes in bone mineral density (BMD) and body composi-
tion occur during puberty. In the present longitudinal study, we eval-
uated BMD and calculated volumetric BMD [bone mineral apparent
density (BMAD)], bone metabolism, and body composition of children
(32 girls and 2 boys) with central precocious and early puberty before
and during treatment with GnRH agonist (GnRH). Patients were
studied at baseline and during treatment for 6 months (n 5 34), 1 yr
(n 5 33), and 2 yr (n 5 16). Lumbar spine and total body BMD and
body composition were measured with dual-energy x-ray absorpti-
ometry. The variables were compared with age- and sex-matched
reference values of the same population and expressed as SD score
(SDS). Bone age was assessed. Serum calcium, phosphate, alkaline
phosphatase, osteocalcin, the carboxyterminal propeptide of type I
collagen (PICP), cross-linked telopeptide of collagen I (ICTP), 1,25
dihydroxyvitamin D and urinary hydroxyproline/creatinine, and cal-
cium/creatinine ratios were measured.
Mean lumbar spine BMD SDS was significantly higher than zero
at baseline (P , 0.02) and did not differ from normal, after 2 yr of
treatment. Mean spinal BMAD SDS and total body BMD SDS were
not significantly different from zero at baseline and had not changed
significantly after 2 yr of treatment. During therapy, fat mass and
percentage body fat SDS increased, whereas lean tissue mass SDS
decreased. Mean lumbar spine BMD and BMAD and total body BMD
SDS, calculated for bone age, were all lower than zero at baseline
(BMD P , 0.001 and BMAD P , 0.05) and also after 2 yr treatment
(respectively, P , 0.001, P , 0.05, and P , 0.01). Biochemical bone
parameters were significantly higher than prepubertal values at
baseline, and they decreased during treatment. In conclusion, pa-
tients with central precocious and early puberty had normal BMD for
chronological age but low BMD for bone age, after 2 yr of treatment
with GnRH. Bone turnover decreased during treatment. Changes in
body composition resembled those seen in patients with GH defi-
ciency. (J Clin Endocrinol Metab 83: 370–373, 1998)
DURING puberty, bone mineral density (BMD) and heightincrease, and body composition changes markedly (1–
4). In central precocious puberty, the hythalamus-pituitary-go-
nadal axis is activated before the age of 8 yr in girls and before
the age of 9 yr in boys. Precocious puberty is associated with
premature and rapid skeletal maturation, leading to decreased
final height, compared with target height, in most patients (5,
6). GnRH agonist (GnRH) can be supplied to arrest pubertal
development to improve final height and avoid psychosocial
problems (7–9). In children with central early puberty, final
adult height may be slightly improved with GnRH treatment
(9). In the present study, both children with central precocious
puberty and children with central early puberty who started
treatment with GnRH were included. Treatment with GnRH
causes a decline in gonadal sex steroids, which may affect BMD,
bone metabolism, and body composition. Some studies in chil-
dren with central precocious puberty showed a decrease of
BMD after 6 and 12 months of treatment with GnRH (10, 11);
another study reported no change during treatment (12). In
women with endometriosis and in elderly men with benign
prostatic hyperplasia, BMD decreased, and biochemical mark-
ers of bone turnover increased during treatment with GnRH
(13, 14).
The aim of the present study was to investigate BMD, bone
metabolism, and body composition of children with central




At diagnosis all patients had a history of increased growth velocity,
girls had breast development Tanner stage 2 or more and boys genital
development Tanner stage 2 or more and testis volume 4 mL or more,
bone age was advanced more than 1 yr beyond chronological age, and
a GnRH-stimulated serum LH concentration greater than 10 IU/L.
Thirty-four patients participated in the study. Twenty-three girls and 2
boys had true idiopathic central precocious puberty. Seven girls had
idiopathic central early puberty: in 3 girls the appearance of pubertal
signs started before the age of 9 yr and in 4 girls before the age of 10 yr.
Two girls had organic CPP: one had a meningomyelocele and the other
a hydrocephalus with a start of puberty before the age of respectively
9 and 8 yr. Median age at start of treatment was 8.7 yr (range 2.8 to 10.8).
All patients received therapy with depot leuprolide-acetate 3.75 mg
(Lucrin depot, Abbott, Amsterdam, The Netherlands) given subcutane-
ously every 4 weeks. During the first month it was given every 2 weeks.
Puberty suppression was evaluated by clinical evaluation, repeating
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GnRH stimulation test after 3 months, by measuring basal serum levels
of LH, follicle stimulating hormone and estradiol/testosterone every 6
months, and bone age assessment. All children had complete suppres-
sion of plasma concentrations of LH and follicle stimulating hormone
during the GnRH test after 3 months of treatment (levels below 5 IU/L).
During treatment with GnRH all children except one girl had basal sex
steroids concentrations equal or less than prepubertal levels (estradiol
below 50 pmol/L, testosterone below 1 nmol/L). In the girl with in-
complete suppression the dose of leuprolide-acetate was doubled. In the
first year the mean ratio of the change of bone age and change of
chronological age was 0.72 and in the second year, 0.47.
Thirty-four patients had baseline and half-year measurements, 33 of
them had 1-yr measurements and 16 children (15 girls and 1 boy) had
2-yr follow-up. One girl stopped treatment after 6 months, and one
stopped after 1 yr. The other children are still included in this ongoing
study. No BMD sd for chronological age could be calculated for 1 girl,
2.8 yr old, because our reference data start from the age of 4 yr. Her data
could be used in the evaluation of BMD sd calculated for bone age.
Methods
Anthropometry, BMD, and body composition measurements and as-
sessment of biochemical bone parameters were performed at baseline and
during GnRH treatment for 6 months, 1 yr, and 2 yr. Height was measured
with a Harpenden stadiometer (Holtain Ltd., Crymmyth, UK). Height was
compared with age- and sex-matched reference values (15) and expressed
as sd score (SDS). Body mass index was calculated as weight/(height)2
(kg/m2) and compared with age- and sex-matched reference values (16)
and expressed as SDS. Pubertal development was determined according to
Tanner (17).
BMD (g/cm2) of the lumbar spine and total body was measured by
dual-energy x-ray absorptiometry (DXA) (Lunar, DPXL/PED, Lunar
Radiation Corporation, Madison, WI). The coefficient of variation has
been reported as 1.04% for lumbar spine and 0.64% for total body (18).
The coefficient of variation (sd) for lumbar spine in our setting is 1.1
(0.2)%. Ancillary DXA-derived data were used to calculate lumbar spine
volumetric BMD [bone mineral apparent density (BMAD)] with the
model BMAD 5 BMD 3 [4/(p 3 width)], as validated before (19). BMD
and BMAD results were compared with our age- and sex-matched Dutch
reference values (2) and expressed as SDS. With the total body mea-
surement by DXA, the body composition was measured as lean tissue
mass, fat mass, and bone mineral content. The coefficients of variation
have been reported as 2.2% for fat mass, 1.1% for lean tissue mass, and
0.6% for bone mineral content (18). Bone mineral content, lean tissue
mass, fat mass, and percentage body fat were compared with our age-
and sex-matched Dutch reference values and expressed as SDS (3).
Bone age was assessed by one investigator using an x-ray of the left
hand, according to the Greulich and Pyle method (20), at baseline in 34
patients, after 6 months in 21 patients, after 1 yr in 32 patients, and after
2 yr in 16 patients.
Blood samples were taken for the assessment of calcium, phosphate,
alkaline phosphatase, 1,25 dihydroxyvitamin D, osteocalcin, the car-
boxyterminal propeptide of type I collagen (PICP), and cross-linked
telopeptide of collagen I (ICTP) in the afternoon (between 1330 h and
1600 h). Samples were not collected on 2 patients at baseline and 2 other
patients at 1 yr. Osteocalcin was measured by RIA (Incstar Corporation,
Stillwater, ), and 1,25 dihydroxyvitamin D was measured by RIA of
Immuno Diagnostic Systems (Boldon, United Kingdom). PICP and ICTP
were measured with an RIA kit (Orion Diagnostica, Espoo, Finland). Our
own reference values for prepubertal healthy children for osteocalcin,
PICP, and ICTP (respectively n 5 25, n 5 82, and n 5 88) were used. In
the first morning void of urine, the ratio of hydroxyproline/creatinine
(OHP/creat) and the ratio of calcium/creatinine (CA/creat) were eval-
uated. Reference values of Wolthers et al. (21) were used for OHP/creat.
LH and FSH were assessed by RIA (Medgenix, Fleurus, Belgium), and
estradiol and testosterone were assessed by RIA of Orion Diagnostica.
Statistical analysis
One-sample t tests were performed to compare the mean SDS values
with normal. We tested to determine whether the average within-patient
change differed from zero (with one-sample t test). Pearson correlation
coefficient was calculated to test the association between two variables
with a normal distribution. Spearman’s rank correlation coefficient was
used, in case of a nonnormal distribution.
Results
The results of BMD, BMAD, body composition, height,
and body mass index measurements, before and during
GnRH treatment, are shown in Table 1.
At baseline, mean lumbar spine BMD SDS was signifi-
cantly higher than zero, which is the mean SDS of age-and
sex-matched healthy controls. Lumbar spine BMD SDS in-
creased during the first 6 months of therapy and decreased
between 6 months and 1 yr of treatment (P , 0.01). After 2
yr, lumbar spine BMD SDS was not significantly different
from normal. Mean lumbar spine BMAD SDS and total body
BMD SDS were not significantly different from normal at
baseline. Lumbar spine BMAD SDS showed a transient in-
crease after 6 months of treatment. Total body BMD SDS
remained stable during treatment.
Mean total body bone mineral content SDS, lean tissue
mass SDS, fat mass SDS, and percentage body fat SDS were
significantly higher than zero at baseline. Total body bone
mineral content SDS had increased after 6 months and 1 yr
of treatment, compared with baseline. Lean tissue mass SDS
decreased significantly during treatment, whereas fat mass
SDS and percentage body fat SDS increased.
Mean height SDS and body mass index SDS were higher
than zero at baseline. Mean height SDS had decreased after
2 yr of treatment. Body mass index SDS increased during
treatment.
TABLE 1. Mean (SD) of variables at baseline and during treatment with GnRH (Rx) in children with CPP
Baseline 6-months Rx 1-yr Rx 2-yr Rx
n 5 33 n 5 33 n 5 32 n 5 16
Lumbar spine BMD SDS 0.51 (1.14)3 0.72 (1.04)1,b 0.53 (1.04)3 0.11 (0.81)
Lumbar spine BMAD SDS 0.18 (1.21) 0.42 (1.10)4,c 0.30 (1.24) 20.01 (1.04)
Total body BMD SDS 0.09 (1.21) 0.24 (1.27) 0.35 (1.08) 0.16 (0.72)
Total body BMC SDS 0.60 (1.17)2 0.83 (1.13)1,c 0.88 (1.17)1,d 0.70 (1.17)4
Lean tissue mass SDS 0.91 (1.19)1 0.74 (1.10)1,b 0.67 (1.10)2,b 0.33 (1.27)b
Fat mass SDS 0.38 (0.89)4 0.76 (0.94)1,a 0.98 (0.93)1,a 1.02 (1.13)2,b
% Body fat SDS 0.44 (1.09)4 0.96 (1.15)1,a 1.24 (1.09)1,a 1.39 (1.36)1,a
Height SDS 1.08 (1.20)1 1.09 (1.15)1 0.97 (1.19)1 0.77 (1.21)4,d
Body mass index SDS 0.96 (1.12)1 1.16 (1.12)1,c 1.38 (1.11)1,a 1.37 (1.21)1,c
BMD, bone mineral density (g/cm2); BMAD, bone mineral apparent density (g/cm3); BMC, bone mineral content (g); SDS, SD score. The mean
SDS was compared with normal, and the within-patient change from baseline was tested.
1 P , 0.001, 2 P , 0.01, 3 P , 0.02, 4 P , 0.05 higher than zero.
a P , 0.001, b P , 0.01, c P , 0.02, d P , 0.05 vs. baseline.
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The two boys did not have lumbar spine BMD SDS higher
than zero at baseline. During treatment, all the variables
showed the same pattern as that seen in the girls.
When SDS was calculated for bone age instead of chro-
nological age (SDSBA), mean lumbar spine BMD SDSBA was
20.82 (sd 0.91), mean BMAD SDSBA was 20.46 (sd 1.11), and
mean total body BMD SDSBA was 21.07 (sd 1.05) at baseline,
all significantly lower than zero (lumbar spine and total body
BMD P , 0.001, BMAD P , 0.05). Mean lumbar spine BMD
and BMAD SDSBA and total body BMD SDSBA, after 2 yr of
treatment, were still significantly lower than zero (lumbar
spine BMD P , 0.001, total body BMD P , 0.01, BMAD P ,
0.05) and did not differ significantly from baseline.
The results of biochemical markers of bone metabolism are
shown in Table 2. Mean osteocalcin, PICP, and ICTP at base-
line were significantly higher than those of prepubertal con-
trols (all P , 0.001). These values and alkaline phosphatase
had decreased after 6 months. Mean PICP and ICTP at 6
months and osteocalcin at 12 months were not significantly
different from those of prepubertal controls. Urine CA/creat
had increased after 6 months, and OHP/creat had dimin-
ished after 1 yr. Serum calcium and phosphate were normal
at baseline and did not change significantly during time.
At baseline, lumbar spine BMD SDS correlated with lean
tissue mass SDS (r 5 0.46, P , 0.01) and body mass index SDS
(r 5 0.46, P , 0.01). Total body BMD SDS correlated with fat
mass SDS (r 5 0.44, P , 0.02), percentage body fat SDS (r 5
0.37, P , 0.02), and body mass index SDS (r 5 0.42, P , 0.02).
Height SDS, Tanner stage, or biochemical bone parameters
were not related to lumbar spine BMD or BMAD or total
body BMD SDS. Height SDS correlated with lean tissue mass
SDS (r 5 0.76, P , 0.001) and total body bone mineral content
SDS (r 5 0.58, P , 0.001).
The change between baseline and 2-yr treatment of height
SDS correlated with the change in lumbar spine BMD SDS
(r 5 0.57, P , 0.05), the change in lean tissue mass SDS (r 5
0.77, P , 0.001), and the change in bone mineral content SDS
(r 5 0.69, P , 0.01), and not with the change in total body
BMD SDS or lumbar spine BMAD SDS. The change in levels
of biochemical markers of bone turnover did not correlate
with the change of BMD or BMAD SDS or height SDS.
Discussion
In children with CPP, mean lumbar spine BMD was high,
and spinal BMAD and total body BMD were normal for chro-
nological age. After 2 yr of treatment with GnRH, mean lumbar
spine BMD and BMAD and total body BMD were normal.
Lumbar spine BMD and BMAD and total body BMD for bone
age were low, before and after 2 yr of treatment with GnRH.
During treatment, fat mass and percentage body fat SDS in-
creased, whereas lean tissue mass SDS decreased. Biochemical
markers of bone formation and of bone resorption decreased.
Previous studies reported increased lumbar spine (mea-
sured with DXA) or radius (measured with single photon
absorptiometry) BMD for chronological age, but appropriate
for bone age in girls with CPP (10–12). The higher spinal
BMD at baseline is in agreement with our findings, but we
found decreased BMD for bone age. The discrepancy may be
caused by differences in reference values, differences in as-
sessment of bone age, or differences in timing of start of
treatment. In the present study, reference values of a large
cohort of healthy children, of the same population and mea-
sured on the same DXA apparatus, were used.
Mean spinal BMAD (corrected for estimated bone volume)
was not increased. BMD is an areal density and does not
adjust for bone size completely. Therefore, the high spinal
BMD could be caused by an increase of bone size.
During puberty, estrogens and GH play an important role
in bone mineralization and bone metabolism in girls. In early
puberty, low levels of estradiol stimulate growth and GH
production. A significant increase of GH is seen during early
puberty, with maximal levels at stage III in girls (22). Bone
modeling of new bone and bone remodeling of existing min-
eralized tissue are each ongoing processes in growing chil-
dren. The biochemical markers are not specific for either the
process of bone modeling or remodeling (23). Markers of
bone metabolism are related to growth velocity and increase
maximally during midpuberty (24, 25). From stage III to V
(late puberty), estradiol levels increase significantly, GH lev-
els decrease, and markers of bone formation and markers of
bone resorption decrease (26). In postmenopausal women
and in adults treated with GnRH, the decline of estrogens is
associated with an increase of bone turnover, the opposite of
what happens during late puberty (13, 14). At baseline, the
TABLE 2. Mean (SD) of biochemical parameters at baseline and during GnRH (Rx) in children with CPP
Baseline 6 months Rx 1 year Rx 2 years Rx Reference values
n 5 32 n 5 32 n 5 30 n 5 16
Osteocalcin (mg/L) 23.5 (7.0) 19.0 (5.3)a 15.7 (3.8)b 16.3 (3.3)b 4–20
PICP (mg/L) 494 (190) 321 (141)b 335 (123)b 276 (84)b 77–626
ICTP (mg/L) 18.3 (4.0) 12.8 (2.5)b 12.0 (4.3)b 11.5 (2.6)b 6–19
Alk. phosphatase (U/L) 291 (73) 217 (47)b 221 (53)b 205 (55)b 80–225
1,25 OHD (pmol/L) 136 (47) 129 (52) 119 (42) 123 (28) 39–102
Urine OHP/creat (mg/g) 122 (56) 107 (115) 76 (31)a 67 (27) 17–145
Urine CA/creat 0.20 (0.13) 0.40 (0.28)c 0.25 (0.16) 0.31 (0.18)a
PICP, carboxy terminal propeptide of type I collagen; ICTP, cross-linked telopeptide of type I collagen; Alk. phosphatase, alkaline phos-
phatase; 1,25 OHD, 1,25 dihydroxyvitamin D; OHP/creat and Ca/creat, hydroxyprolin/creatinine and calcium/creatinine (mmol/L per mmol/L)
ratio’s in first morning void of urine. The mean within patient change from baseline was tested.
a P , 0.01.
b P , 0.001.
c P , 0.02.
d P , 0.05 vs. baseline.
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patients had bone turnover comparable with that of adolescents
in early puberty. Bone formation and bone resorption markers
were higher than prepubertal values, probably because of the
increased growth related to early puberty. The markers of bone
turnover decreased to prepubertal levels during treatment. This
mainly reflects a decrease in bone modeling.
Increased GH and/or estrogens levels, associated with early
puberty, may have caused the increase of lumbar spine BMD
at baseline in the girls. Lumbar spine consists of more trabecular
bone than bone of the total body, which is for 80% cortical bone
(27). Bone turnover is higher in trabecular bone (28), which may
explain the differences found between lumbar spine and total
body BMD. Also, in postmenopausal women, change in BMD
is faster in trabecular bone than in cortical bone (29). The initial
increase of lumbar spine BMD and BMAD SDS may be ex-
plained by incomplete suppression of puberty during the first
months. The decrease in spinal BMD, thereafter, is probably
caused by the decline of estrogens and GH. A decrease in
nocturnal GH secretion and subnormal response to GH stim-
ulation tests were described after 3–12 months treatment with
GnRH in children with CPP (10, 30–32). However, no relation
was found between the subnormal GH levels and growth ve-
locity during treatment with GnRH (32). The decline of GH may
explain the decrease of lean tissue mass SDS and the increase
of fat mass and percentage fat SDS. GH is known to have
lipolytic and anabolic effects. Children and adults with GH
deficiency have decreased lean tissue mass and increased fat
mass, which improve during treatment (33–36).
In conclusion, children with CPP have normal BMD for
chronological age but decreased BMD, for bone age, after 2
yr of treatment with GnRH. Puberty is an important period
for bone accretion. In patients with CPP, pubertal develop-
ment is temporarily inhibited by GnRH. It is unknown
whether BMD increases normally after cessation of GnRH
and whether the patients reach a normal peak bone mass.
Long-term longitudinal studies, till peak bone mass is
achieved, are needed to evaluate BMD and body composition
after cessation of treatment.
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